Skip to main content
. 2024 May 24;46(5):4671–4688. doi: 10.1007/s11357-024-01204-1

Table 6.

Safety evaluation of study subjects before (0 W) and after (12 W) NMN intervention

Unit Placebo group NMN group ANCOVA
Systolic blood pressure mmHg 0 W 124  ±  19 124  ±  12
12 W 124  ±  19 122  ±  15 0.494
Diastolic blood pressure mmHg 0 W 77  ±  13 75  ±  10
12 W 77  ±  13 74  ±  11 0.557
Pulse rate bpm 0 W 71  ±  9 69  ±  10
12 W 73  ±  9 69  ±  9 0.157
White blood cells /μL 0 W 5356.2  ±  1084.1 5339.3  ±  1571.8
12 W 5166.9  ±  1257.3 5086.7  ±  1819.7 0.749
Red blood cells  × 104/μL 0 W 446.6  ±  33.5 458.5  ±  37.1
12 W 441.4  ±  37.6 451.4  ±  41.2 0.631
Hemoglobin g/L 0 W 137.5  ±  11.1 140.1  ±  10.6
12 W 137.1  ±  12.2 140.0  ±  11.6 0.470
Hematocrit % 0 W 0.43  ±  0.03 0.44  ±  0.03
12 W 0.42  ±  0.03 0.42  ±  0.03 0.582
Platelets  × 104/μL 0 W 24.5  ±  5.0 25.0  ±  4.6
12 W 24.2  ±  4.8 25.0  ±  4.3 0.568
Total protein g/L 0 W 70.41  ±  2.44 71.73  ±  3.49
12 W 70.86  ±  2.76 72.27  ±  3.60 0.521
Albumin g/L 0 W 43.17  ±  2.80 43.77  ±  2.25
12 W 42.90  ±  2.76 43.73  ±  2.03 0.333
Total bilirubin mg/dL 0 W 0.79  ±  0.26 0.73  ±  0.22
12 W 0.79  ±  0.31 0.77  ±  0.25 0.477
Alkaline phosphatase IU/L 0 W 73.4  ±  18.0 64.1  ±  19.7
12 W 73.3  ±  17.0 63.2  ±  18.8 0.214
Lactate dehydrogenase IU/L 0 W 178.9  ±  20.5 180.5  ±  30.4
12 W 170.2  ±  15.8 175.5  ±  28.3 0.999
Aspartate aminotransferase IU/L 0 W 22.2  ±  3.7 23.7  ±  4.8
12 W 22.1  ±  5.0 23.3  ±  5.1 0.858
Alanine aminotransferase IU/L 0 W 16.9  ±  4.4 19.7  ±  7.2
12 W 16.4  ±  5.3 18.4  ±  5.6 0.771
Gamma-glutamyl transpeptidase IU/L 0 W 30.6  ±  20.1 23.8  ±  13.3
12 W 29.9  ±  20.6 23.9  ±  17.2 0.908
Creatine kinase IU/L 0 W 158.1  ±  181.5 113.9  ±  58.8
12 W 114.6  ±  51.7 111.1  ±  56.9 0.233
Total cholesterol mmol/L 0 W 5.79  ±  0.93 5.56  ±  0.88
12 W 5.69  ±  0.88 5.66  ±  1.00 0.194
Triglycerides mmol/L 0 W 1.08  ±  0.61 0.94  ±  0.47
12 W 1.26  ±  0.74 1.04  ±  0.55 0.390
HDL cholesterol mmol/L 0 W 1.77  ±  0.51 1.76  ±  0.38
12 W 1.68  ±  0.52 1.72  ±  0.38 0.194
LDL cholesterol mmol/L 0 W 3.34  ±  0.65 3.15  ±  0.72
12 W 3.19  ±  0.71 3.21  ±  0.76 0.146
Urea nitrogen mmol/L 0 W 5.60  ±  1.44 6.04  ±  1.28
12 W 5.38  ±  1.00 5.69  ±  1.13 0.650
Creatinine μmol/L 0 W 73.55  ±  13.91 72.28  ±  14.65
12 W 67.58  ±  14.32 67.66  ±  14.96 0.354
Uric acid μmol/L 0 W 340.9  ±  73.0 320.4  ±  75.2
12 W 343.3  ±  83.6 326.0  ±  82.5 0.797
Sodium mmol/L 0 W 140.8  ±  1.6 142.0  ±  1.5
12 W 139.2  ±  1.7 139.5  ±  1.6 0.897
Potassium mmol/L 0 W 4.38  ±  0.35 4.52  ±  0.27
12 W 4.36  ±  0.25 4.50  ±  0.36 0.219
Chloride mmol/L 0 W 104.4  ±  1.7 104.5  ±  2.2
12 W 103.9  ±  1.8 103.4  ±  2.1 0.204
Calcium mmol/L 0 W 2.30  ±  0.07 2.35  ±  0.06
12 W 2.33  ±  0.07 2.37  ±  0.09 0.545
Glucose mmol/L 0 W 5.28  ±  0.47 5.45  ±  0.46
12 W 5.19  ±  0.36 5.35  ±  0.40 0.443
HbA1c(NGSP) % 0 W 5.49  ±  0.31 5.45  ±  0.26
12 W 5.47  ±  0.30 5.46  ±  0.27 0.616

Means ± standard deviation are shown

Safety analysis population: N = 59 (placebo group N = 29, NMN group N = 30)